Jun 22, 2022 7:00am EDT ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
May 13, 2022 7:00am EDT ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
May 03, 2022 7:00am EDT Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
Apr 28, 2022 7:00am EDT ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
Apr 19, 2022 7:00am EDT ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer